GT Biopharma Reports Third Quarter 2026 Financial Results
GT Biopharma reported a net loss of approximately $3.5 million and a loss from operations of approximately $3.5 million for the quarter ended September 30, 2026. Cash and cash equivalents were approximately $10 million, which the company anticipated would fund operations into Q3 2027. Enrollment continued in Phase 1 trials of GTB-3650 and GTB-5550, with updates anticipated in Q4 2026.
Key takeaways
The company reported a Q3 2026 net loss of approximately $3.5 million versus net income of $8.3 million in Q3 2025, primarily reflecting $11.4 million of non-cash other income from the change in fair value of the Greenshoe Rights liability in the prior-year quarter.
Loss from operations was approximately $3.5 million in Q3 2026 compared with approximately $3.4 million in Q3 2025.
R&D expenses increased by $1.1 million to approximately $1.7 million, primarily because of higher material costs, while SG&A expenses excluding stock compensation decreased by $0.6 million to approximately $1.8 million.
Cash and cash equivalents were approximately $10 million as of September 30, 2026 and were anticipated to provide sufficient funding for operations into Q3 2027.
The GTB-3650 Phase 1 dose-escalation study had completed Cohort 4, with enrollment in Cohort 5 in progress and an update expected in Q4 2026.
The GTB-5550 Phase 1 solid-tumor trial had completed enrollment in Cohorts 1 and 2, with Cohort 3 enrollment in progress and an update expected in Q4 2026.
GTB-5550 received FDA clearance for a new IND in multiple myeloma under an investigator-sponsored trial protocol, with Phase 1 initiation contingent upon timing and receipt of non-dilutive grant funding.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow GTBP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.